BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee SJ, Baek K, Lee S, Lee YJ, Park JE, Lee SG. Post-Marketing Pooled Safety Analysis for CT-P13 Treatment of Patients with Immune-Mediated Inflammatory Diseases in Observational Cohort Studies. BioDrugs 2020;34:513-28. [PMID: 32356239 DOI: 10.1007/s40259-020-00421-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Hideo Sakane, Koichi Okamura, Makoto Inoue, Hiroshi Inoue, Yukio Yonemoto, Hirofumi Mitomi, Kosei Tsuchida, Takahito Suto, Tetsuya Kaneko, Hirotaka Chikuda. Anti-drug antibodies and rheumatoid factor level in patients with rheumatoid arthritis using the infliximab biosimilar CT-P13. BMC Rheumatol 2022;6:74. [PMID: 36474258 DOI: 10.1186/s41927-022-00304-9] [Reference Citation Analysis]
2 Kurki P, Kang HN, Ekman N, Knezevic I, Weise M, Wolff-Holz E. Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience. BioDrugs 2022;36:359-71. [PMID: 35596890 DOI: 10.1007/s40259-022-00533-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Lee SS, Kim TH, Park W, Song YW, Suh CH, Kim SK, Yoo DH. Impact of Infliximab Biosimilar CT-P13 Dose and Infusion Interval on Real-World Drug Survival and Effectiveness in Patients with Ankylosing Spondylitis. J Clin Med 2021;10:4568. [PMID: 34640586 DOI: 10.3390/jcm10194568] [Reference Citation Analysis]
4 Cheon JH, Nah S, Kang HW, Lim YJ, Lee SH, Lee SJ, Kim SH, Jung NH, Park JE, Lee YJ, Jeon DB, Lee YM, Kim JM, Park SH. Infliximab Biosimilar CT-P13 Observational Studies for Rheumatoid Arthritis, Inflammatory Bowel Diseases, and Ankylosing Spondylitis: Pooled Analysis of Long-Term Safety and Effectiveness. Adv Ther 2021;38:4366-87. [PMID: 34250583 DOI: 10.1007/s12325-021-01834-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Sagami S, Nishikawa K, Yamada F, Suzuki Y, Watanabe M, Hibi T. Post-marketing analysis for biosimilar CT-P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan. J Gastroenterol Hepatol 2021;36:2091-100. [PMID: 33450057 DOI: 10.1111/jgh.15399] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Taylor PC, Christensen R, Moosavi S, Selema P, Guilatco R, Fowler H, Mueller M, Liau KF, Haraoui B. Real-life drug persistence in patients with rheumatic diseases treated with CT-P13: a prospective observational cohort study (PERSIST). Rheumatol Adv Pract 2021;5:rkab026. [PMID: 34377890 DOI: 10.1093/rap/rkab026] [Reference Citation Analysis]
7 Kim JW, Jung JY, Suh CH. Real-world observational study of biosimilars in inflammatory arthritis treatment: a systematic literature review. Expert Opin Biol Ther 2021;21:57-73. [PMID: 32808557 DOI: 10.1080/14712598.2020.1812575] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]